Kera Capital Partners Inc. Acquires Shares of 26,849 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Kera Capital Partners Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 26,849 shares of the company’s stock, valued at approximately $218,000.

Other institutional investors also recently modified their holdings of the company. Jennison Associates LLC raised its stake in Phathom Pharmaceuticals by 112.7% during the third quarter. Jennison Associates LLC now owns 5,866,389 shares of the company’s stock valued at $106,064,000 after buying an additional 3,108,810 shares during the last quarter. FMR LLC raised its position in shares of Phathom Pharmaceuticals by 49,000.7% in the 3rd quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after purchasing an additional 1,301,458 shares during the last quarter. Checkpoint Capital L.P. raised its position in shares of Phathom Pharmaceuticals by 71.9% in the 3rd quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock worth $27,198,000 after purchasing an additional 629,307 shares during the last quarter. Portolan Capital Management LLC boosted its stake in Phathom Pharmaceuticals by 50.4% in the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock worth $30,735,000 after purchasing an additional 569,829 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Phathom Pharmaceuticals during the 3rd quarter valued at about $7,952,000. 99.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PHAT has been the subject of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

Insider Activity at Phathom Pharmaceuticals

In other news, Director Frank Karbe acquired 12,500 shares of Phathom Pharmaceuticals stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $7.93 per share, for a total transaction of $99,125.00. Following the completion of the transaction, the director now owns 57,000 shares in the company, valued at $452,010. The trade was a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 24.10% of the stock is owned by insiders.

Phathom Pharmaceuticals Price Performance

Shares of NASDAQ PHAT opened at $6.96 on Monday. The firm’s 50-day moving average price is $8.31 and its 200-day moving average price is $12.61. Phathom Pharmaceuticals, Inc. has a 52-week low of $6.07 and a 52-week high of $19.71. The company has a market cap of $475.92 million, a PE ratio of -1.22 and a beta of 0.56.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.